The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that controls plasma LDL cholesterol levels by posttranslational regulation of the LDL receptor (LDLR). Previously, we showed that PCSK9 binds specifically to an EGF-like repeat (EGF-A) in LDLR and reroutes the receptor from endosomes to lysosomes rather than to the cell surface. Here, we defined the regions in LDLR and PCSK9 that are required for receptor degradation and examined the relationship between PCSK9 binding and LDLR conformation. Addition of PCSK9 to cultured hepatocytes promoted degradation of WT LDLR and of receptors lacking up to four ligand binding domains, EGF-B or the clustered O-linked sugar region. In contrast, LDLRs lacking the entire ligand binding domain or the β-propeller domain failed to be degraded, although they bound and internalized PCSK9. Using gel filtration chromatography, we assessed the effects of PCSK9 binding on an acid-dependent conformational change that happens in the extracellular domain of the LDLR. Although PCSK9 prevented the reduction in hydrodynamic radius of the receptor that occurs at a reduced pH, the effect was not sufficient for LDLR degradation. A truncated version of PCSK9 containing the prodomain and the catalytic domain, but not the C-terminal domain, bound the receptor but did not stimulate LDLR degradation. Thus, domains in both the LDLR and PCSK9 that are not required for binding (or internalization) are essential for PCSK9-mediated degradation of the LDLR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PCSK9 prevents LDLR recycling and reduces ApoE uptake.
“The activity of LDLR is tightly regulated by PCSK9, as it prevents its recycling to the surface and subsequently reduces ApoE uptake [31][32][33] .”
From ApoE4 impairs astrocyte lipid droplet formation via endolysosomal dysfunction (2026) · cites this paper as [32]
An LDLR lacking the ligand binding domain is able to internalize PCSK9 but is not degraded and instead recycles back to the plasma membrane.
“A series of deletion studies demonstrate that an LDLR lacking the ligand binding domain is able to internalize PCSK9 but is not degraded and instead recycles back to the plasma membrane126,127.”
From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Davis, C. G., Goldstein, J. L., Südhof, T. C., Anderson, R. G. W., Russell, D. W., & Brown, M. S. (1987) · Nature · doi:10.1038/326760a0 · Cited by 411
Lalanne, F., Lambert, G., Amar, M. J. A., Chétiveaux, M., Zaïr, Y., Jarnoux, A.-L., Ouguerram, K., Friburg, J., Seidah, N. G., Brewer, H. B., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400396-jlr200 · Cited by 104
Flagged first, then by citations
Research works printed but not linked: 34
- J Goldstein, H Hobbs, M Brown, C Scriver, A Beaudet, W Sly, D Valle The Metabolic and Molecular Bases of Inherited Disease (McGraw Hill, New York), pp. 2863–2913 (2001).
- 10.1016/S0022-2275(20)42605-7 · DOI · Paper page
- 10.1126/science.1060458 · DOI · Paper page
- 10.1038/ng1161 · DOI · Paper page
- 10.1073/pnas.0335507100 · DOI · Paper page
- 10.1016/j.abb.2003.09.011 · DOI
- 10.1038/nsmb1235 · DOI · Paper page
- 10.1016/j.str.2007.04.004 · DOI · Paper page
- 10.1172/JCI29383 · DOI · Paper page
- 10.1093/hmg/ddl077 · DOI · Paper page
- 10.1074/jbc.C700095200 · DOI · Paper page
- 10.1042/BJ20070664 · DOI
- 10.1194/jlr.M300203-JLR200 · DOI · Paper page
- 10.1073/pnas.1534923100 · DOI · Paper page
- 10.1073/pnas.95.11.5987 · DOI · Paper page
- 10.1073/pnas.0402133101 · DOI · Paper page
- 10.1074/jbc.M410077200 · DOI · Paper page
- 10.1016/j.tibs.2006.12.008 · DOI · Paper page
- 10.1126/science.1078124 · DOI · Paper page
- 10.1074/jbc.M702027200 · DOI · Paper page
- 10.1074/jbc.M701634200 · DOI · Paper page
- 10.1126/science.2988123 · DOI · Paper page
- 10.1006/jmbi.1998.2115 · DOI
- 10.1073/pnas.0703402104 · DOI
- 10.1016/0092-8674(81)90340-8 · DOI · Paper page
- 10.1073/pnas.0712064105 · DOI · Paper page
- 10.1016/j.molcel.2004.09.038 · DOI
- 10.1016/0076-6879(83)98152-1 · DOI
- 10.1016/S0021-9258(18)47706-X · DOI · Paper page
- 10.1016/0092-8674(84)90388-X · DOI · Paper page
- 10.1016/S0021-9258(19)69566-9 · DOI
- 10.1016/0092-8674(84)90188-0 · DOI · Paper page
- 10.1016/S0021-9258(18)37702-0 · DOI · Paper page
- 10.1016/S0021-9258(17)35862-3 · DOI
Cited by
Sorted by citations
Mechanisms and regulation of cholesterol homeostasis
Luo, J., Yang, H., & Song, B.-L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0190-7 · Cited by 1,980
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Feedback Regulation of Cholesterol Uptake by the LXR–IDOL–LDLR Axis
Zhang, L., Reue, K., Fong, L. G., Young, S. G., & Tontonoz, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.250571 · Cited by 137
Targeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113035 · Cited by 107
Alabi, A., Xia, X.-D., Gu, H.-M., Wang, F., Deng, S.-J., Yang, N., Adijiang, A., Douglas, D. N., Kneteman, N. M., Xue, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22167-3 · Cited by 63
Self-citationButkinaree, C., Canuel, M., Essalmani, R., Poirier, S., Benjannet, S., Asselin, M.-C., Roubtsova, A., Hamelin, J., Marcinkiewicz, J., Chamberland, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.647180 · Cited by 53
PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling
Guan, Y., Liu, X., Yang, Z., Zhu, X., Liu, M., Du, M., Pan, X., & Wang, Y. (2025) · Circulation · doi:10.1161/circulationaha.124.072336 · Cited by 50
PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum
Strøm, T. B., Tveten, K., & Leren, T. P. (2014) · Biochemical Journal · doi:10.1042/bj20130930 · Cited by 48
Pathways and Molecular Mechanisms Governing LDL Receptor Regulation
Schmidt, H. M., Jarrett, K. E., de Aguiar Vallim, T. Q., & Tarling, E. J. (2025) · Circulation Research · doi:10.1161/circresaha.124.323578 · Cited by 33
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
Wang, M., Alabi, A., Gu, H.-M., Gill, G., Zhang, Z., Jarad, S., Xia, X.-D., Shen, Y., Wang, G.-Q., & Zhang, D.-W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.917238 · Cited by 13
Self-citationMazura, A. D., & Pietrzik, C. U. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041268 · Cited by 9
ApoE4 impairs astrocyte lipid droplet formation via endolysosomal dysfunction
Ralhan, I., Bae, J.-Y., Lee, N. Y., Cai, W., Chang, J., Jarad, S., Gu, H., Zhang, D., & Ioannou, M. S. (2026) · doi:10.64898/2026.09.01.748585
Self-citation
Metadata
- Authors
- Zhang, D.-W., Garuti, R., Tang, W.-J., Cohen, J. C., & Hobbs, H. H.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-09-02
- Volume
- 105
- Issue
- 35
- Pages
- 13045-13050
- ISSN
- 0027-8424
- 1091-6490
- Cited by
- 208
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review